Mesna Baxter Healthcare (Mesna)

Mesna chemically binds to acrolein, the urotoxic metabolite formed during cyclophosphamide and ifosfamide metabolism. This binding creates a non‑reactive compound that is rapidly eliminated in the urine, shielding the bladder lining from damage.

The dose of Mesna is individualized by the prescribing oncologist based on the specific chemotherapy regimen, the dose of cyclophosphamide or ifosfamide, and the patient’s renal function. Exact dosing schedules are not standardized and must follow the prescriber’s order.

Mesna is classified as Pregnancy Category B, indicating that animal studies have not shown risk to the fetus and there are no adequate human studies. It may be used during pregnancy or lactation only if the potential benefit justifies the potential risk; a healthcare professional should evaluate each case.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and the necessary import documentation.

Mesna is the most widely used agent for preventing acrolein‑induced cystitis because it directly detoxifies the metabolite. Alternatives such as sodium thiosulfate are used for different toxicities (e.g., cisplatin‑induced ototoxicity) and are not as effective for cyclophosphamide‑related bladder protection.

Mesna injection solution should be stored at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use to maintain stability.

Mesna is given intravenously, usually as a separate infusion before, during, or after the chemotherapy dose, according to the treating physician’s protocol. Administration is performed by qualified healthcare personnel in a clinical setting.

The most serious adverse reactions include anaphylactic or severe hypersensitivity reactions, profound hypotension or shock, pulmonary edema, and acute renal failure. Immediate medical attention is required if any of these symptoms develop.

Mesna should be avoided in patients with known hypersensitivity to the drug or its components, and in those with severe renal impairment where adequate clearance cannot be ensured. Caution is also advised for patients with uncontrolled cardiovascular instability.